In plain language

An unusual response can be scientifically important. Case reports make observations visible and help researchers identify questions that a larger study might test. They are especially useful for rare tumors or unexpected clinical courses.

The PRaG-related literature includes cases from Wuhan, Sichuan and Guangxi. These reports show that clinicians at different institutions have explored related approaches. They do not, by themselves, establish how often a response will occur.

What is missing from a case report?

Usually there is no comparison group and no representative denominator. We do not know from one favorable case how many similar patients might have received the treatment without the same result. Previous and concurrent therapies can also contribute.

A complete response is an assessment category. It does not automatically mean cure. The duration and completeness of follow-up remain important.

Different questions require different designs

A cohort can estimate outcomes in a defined patient group. A nonrandomized comparison can explore differences but remains vulnerable to confounding. A randomized comparison can better address whether treatment itself causes a difference, provided it is well designed and conducted.

The 2025 MSS colorectal cancer comparison illustrates why all endpoints matter: a reported PFS signal accompanied no statistically significant overall-survival difference. Selecting only the favorable endpoint would change the meaning of the paper.

Keeping a human perspective

For the person described, symptom relief or a prolonged response may be profoundly meaningful. We can acknowledge that importance while keeping an individual experience separate from a general treatment claim. That is the balance this resource aims to maintain.

Sources and related publications